1st Quarter - Report

WILLIAMS AND JENSEN, PLLC for MERCK & CO INC

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to corporate tax including international tax proposals: Implementation of H.R. 1 Tax Cuts Jobs Act.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN COS, Rep Van Hilleary and Majority Whip
CHERYL LYNN JAEGER —
NICHOLAS KARELLAS LA to Senator Christopher Bond; Tax Counsel, Rep Lynn Jenkins
KARINA LYNCH —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (115th)

Animals ANI

Monitor issues as they relate to animal health . Issues concerning the Animal Drug User Fee Act.

LobbyistCovered position, as disclosed
SCOTT GRAVES Deputy Chief of Staff, Rep Conaway; COS, Rep Farenthold, COS, Rep Conaway; Staff Director, House Ag Committee
CHERYL LYNN JAEGER New Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Plicy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox
KARINA LYNCH Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs.
ERIN BOOK MULLEN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Medicare/Medicaid MMM

Payment policies for Part B prescription drugs; rebates and co-pays for Medicare Part D drug benefits; possible revisions in structure and operation of Medicare drug policies; ; Rebates for Medicare Part D

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker and Ofc of VA 7th; Sr Policy Advisor, Majority Leader, Rep. Eric Cantor; Sr. Advisor, Majority Whip, Rep Roy Blunt; Prof Staff House Committee on E&C; Sr LA to Rep. Christopher Cox
KARINA LYNCH —
GEORGE OLSEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Health Issues HCR

Drug safety; Congressional oversight issues; Issues related to vaccines and drug pricing; Drug pricing under 340B program; H.R. 1628, American Health Care Act of 2017; General education about FDA approval policies.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
CHERYL LYNN JAEGER —
KARINA LYNCH —
GEORGE OLSEN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 1628 (115th)

Trade (domestic/foreign) TRD

International trade issues and agreements; Monitor pending trade issues.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
KARINA LYNCH —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act 2018. H.R. 1892, the Bipartisan Budget Act of 2018.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN New COS, Rep Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA New —
CHERYL LYNN JAEGER New Shrd employee, Ofc of the Speaker & Ofc of VA 7;Sr policy adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
KARINA LYNCH New Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Government Affairs

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 1892 (115th), H.R. 1625 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.